EP0349239A2 — Condensed pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
Assigned to Smith Kline and French Laboratories Ltd · Expires 1990-01-03 · 36y expired
What this patent protects
Compounds of the formula (1) : and pharmaceutically acceptable salts are described wherein is a ring of sub-formula (a), (b) or (c): X is oxygen or sulphur, and R¹ is C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₅cycloalkylC₁₋₄alkyl, or C₁₋₄alkyl substituted by 1 to 6 fluoro gro…
USPTO Abstract
Compounds of the formula (1) : and pharmaceutically acceptable salts are described wherein is a ring of sub-formula (a), (b) or (c): X is oxygen or sulphur, and R¹ is C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₅cycloalkylC₁₋₄alkyl, or C₁₋₄alkyl substituted by 1 to 6 fluoro groups. Their use as medicaments, pharmaceutical compositions containing them and processes for their preparation are also described.
Drugs covered by this patent
- Otezla (APREMILAST) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.